Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Classification and prognostic variables in myelomatosis.

O P Hansen, D A Galton

    Scandinavian Journal of Haematology
    |July 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study.

    Cancer chemotherapy and pharmacology·2001
    Same author

    Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17).

    Leukemia·2000
    Same author

    Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.

    Leukemia·1997
    Same author

    [Treatment of primary breast cancer. Consequences of mammographic screening in the municipality of Copenhagen].

    Ugeskrift for laeger·1996
    Same author

    Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.

    Anti-cancer drugs·1995
    Same author

    Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.

    Journal of the National Cancer Institute·1994

    Comparing multiple myeloma treatment trials is challenging due to varying diagnostic criteria and patient eligibility. Standardizing entry criteria and using prognostic groupings can improve result comparability and identify patient subgroups for further research.

    Area of Science:

    • Hematology
    • Clinical Trials
    • Oncology

    Background:

    • Comparing treatment outcomes in multiple myeloma clinical trials is hindered by inconsistent diagnostic criteria and patient selection.
    • Variations in patient populations and outcome recording methods across studies complicate direct result comparisons.

    Purpose of the Study:

    • To highlight the need for standardized diagnostic criteria and patient entry criteria in multiple myeloma trials.
    • To propose methods for improving the comparability of treatment results across different myelomatosis studies.
    • To explore the relationship between prognostic groupings, treatment response, and survival outcomes.

    Main Methods:

    • Review of existing challenges in comparing myelomatosis trial results.
    • Discussion of the impact of diagnostic heterogeneity on patient series composition.

    Related Experiment Videos

  • Analysis of the utility of prognostic groupings for interpreting survival data.

    • Main Results:

    • Inconsistent diagnostic criteria and patient eligibility lead to significant variability in patient populations across myelomatosis trials.
    • Excluding specific conditions like monoclonal gammopathy of uncertain significance and plasma-cell leukemia can enhance trial uniformity.
    • Prognostic groupings aid in interpreting survival patterns but do not correlate with treatment responsiveness.
    • Rapid responders to treatment paradoxically exhibit worse outcomes compared to slow responders.

    Conclusions:

    • Standardizing diagnostic and entry criteria is crucial for reducing variance in survival rates between multiple myeloma trials.
    • Prognostic groupings are valuable for analyzing survival data, but further research is needed to address differential treatment responses.
    • The observation that rapid responders fare worse suggests potential for novel treatment strategies and future randomized trials targeting this subgroup.